Preemptive trials for aGvHD
| ClinicalTrials.gov Identifier: . | Age . | Risk assignment . | No. of patients . | Expected completion . | Intervention . | Outcome to be measured . | Improved outcome . | Ref. . |
|---|---|---|---|---|---|---|---|---|
| NCT05368181 Chengdu, Sichuan, China | Adult | High risk by MAP days 7, 14, 21, 28 | 56 | Dec 2024 | Methylprednisolone starts with the dose of 2 mg/kg for 5 days | High Risk Patients Who Develop Grade III-IV aGvHD by day 100 | Pending | NA |
| NCT03459040 MAGIC consortium | Adults | High risk by day 7 or 14 | 30 | Completed | α1-Antitrypsin | Number of High Risk patients who develop steroid refractory GvHD by day 100 | No | 3 |
| EudraCT number: 2008-005862-30. aGvHD MS-17 | Adults | High risk 14 days before onset | 92 | Completed | Prednisolone 2-2.5 mg/kg for 5 days followed by a taper of 19 days in the absence of aGvHD | Incidence of aGvHD II-IV between randomization and day +100 after HSCT | No | 8 |
| Bagialupo | Adults | High risk by day 7 | 170 | Completed | ATG 1.25 mg/kg intravenously on days 7 and 9 | Primary end point of the study was TRM Secondary end point was acute GvHD grades 3 to 4. | Decreased aGvHD | 10 |
| Storek | Adults | High risk on day 7 | 68 | Completed | ATG day 8 | Reduction in high risk GvHD (both aGvHD and cGvHD) | No | 42 |
| ClinicalTrials.gov Identifier: . | Age . | Risk assignment . | No. of patients . | Expected completion . | Intervention . | Outcome to be measured . | Improved outcome . | Ref. . |
|---|---|---|---|---|---|---|---|---|
| NCT05368181 Chengdu, Sichuan, China | Adult | High risk by MAP days 7, 14, 21, 28 | 56 | Dec 2024 | Methylprednisolone starts with the dose of 2 mg/kg for 5 days | High Risk Patients Who Develop Grade III-IV aGvHD by day 100 | Pending | NA |
| NCT03459040 MAGIC consortium | Adults | High risk by day 7 or 14 | 30 | Completed | α1-Antitrypsin | Number of High Risk patients who develop steroid refractory GvHD by day 100 | No | 3 |
| EudraCT number: 2008-005862-30. aGvHD MS-17 | Adults | High risk 14 days before onset | 92 | Completed | Prednisolone 2-2.5 mg/kg for 5 days followed by a taper of 19 days in the absence of aGvHD | Incidence of aGvHD II-IV between randomization and day +100 after HSCT | No | 8 |
| Bagialupo | Adults | High risk by day 7 | 170 | Completed | ATG 1.25 mg/kg intravenously on days 7 and 9 | Primary end point of the study was TRM Secondary end point was acute GvHD grades 3 to 4. | Decreased aGvHD | 10 |
| Storek | Adults | High risk on day 7 | 68 | Completed | ATG day 8 | Reduction in high risk GvHD (both aGvHD and cGvHD) | No | 42 |
NA, not available; TRM, transplant related mortality.